Pancreaticobiliary Neoplasm

Observed

← altered in cohorts of

KLHDC7A

42 / 51 cases (82 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

MRTO4

42 / 51 cases (82 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

TAS1R2

42 / 51 cases (82 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

TMCO4

42 / 51 cases (82 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

AADACL3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

AADACL4

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ACTL8

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

AHDC1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

AKR7A3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ALDH4A1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ALPL

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ARHGEF10L

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ASAP3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ATP13A2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

C1orf158

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

CAMK2N1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

CAMTA1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

CAPZB

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

CDA

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

CLCN6

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

DDOST

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

DHRS3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

DNAJC11

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

E2F2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ECE1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

EIF4G3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ELOA

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

EMC1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

FAM43B

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

FBXO42

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

HMGCL

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

HNRNPCL2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

HNRNPCL4

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

HNRNPR

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

HP1BP3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

HSPG2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

HTR1D

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

IFFO2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

IGSF21

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

KDM1A

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

KIF17

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

LACTBL1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

LDLRAD2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

LRRC38

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

LUZP1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

MFAP2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

MICOS10

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

MICOS10-NBL1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

MST1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

MUL1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

NBL1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

NBPF1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

NBPF3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

NPHP4

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

OTUD3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PADI2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PADI3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PADI4

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PADI6

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PAX7

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PDIK1L

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PDPN

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PINK1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PITHD1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PLA2G2A

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PLA2G2C

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PLA2G2E

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PLA2G2F

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PLEKHG5

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF12

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF14

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF17

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF18

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF20

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF25

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF26

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF27

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF33

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF5

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF8

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

PRAMEF9

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

RAP1GAP

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

RCC2

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

RNF186

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

RPL11

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

RPL22

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

SH2D5

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

SLC66A1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

SPEN

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

TEX46

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

THAP3

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

UBR4

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

UBXN10

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

USP48

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

VPS13D

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

VWA5B1

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

ZNF436

41 / 51 cases (80 %) · ssm · TCGA-CHOL

—

Observed

← altered in cohorts of

CFAP53

114 / 185 cases (62 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CXXC1

114 / 185 cases (62 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MAPK4

114 / 185 cases (62 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MBD1

114 / 185 cases (62 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ME2

114 / 185 cases (62 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SKA1

114 / 185 cases (62 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

C18orf54

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

DCC

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MBD2

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MEX3C

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MRO

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MYO5B

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

POLI

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

STARD6

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

TCF4

113 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ALPK2

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CCDC68

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

DYM

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

DYNAP

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ELAC1

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

LIPG

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

RAB27B

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB10

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB7

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SMAD7

112 / 185 cases (61 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ACAA2

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ATP5F1A

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ATP8B1

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

C18orf25

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

C18orf32

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CD226

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CDH19

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CDH20

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CDH7

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CPLX4

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CTIF

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

DOK6

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

DSEL

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ELOA2

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

EPG5

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

KDSR

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MALT1

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

NEDD4L

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ONECUT2

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

RELCH

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

RNF152

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

RPL17

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

RPL17-C18orf32

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB11

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB12

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB13

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB4

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB8

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

TMX3

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

TNFRSF11A

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

TXNL1

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

VPS4B

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

WDR7

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ZNF532

111 / 185 cases (60 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

BCL2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

BOD1L2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CCBE1

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CCDC102B

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

CDKN2B

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

FECH

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

GALR1

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

GRP

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

HAUS1

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

HDHD2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

HMSD

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

IER3IP1

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

MC4R

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

NARS1

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

PHLPP1

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

PIAS2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

PIGN

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

PIK3C3

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

PSTPIP2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

RAX

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

RTTN

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SEC11C

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB3

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SERPINB5

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SETBP1

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SKOR2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SLC14A2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

SMAD2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ST8SIA3

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ST8SIA5

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ZBTB7C

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ZCCHC2

110 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

← altered in cohorts of

ELOA3C

109 / 185 cases (59 %) · ssm · TCGA-PAAD

—

Observed

Pancreatic Neuroendocrine Tumor

← altered in cohorts of

MEN1

36 / 98 cases (37 %) · ssm · panet_arcnet_2017 · largest of 2 cohorts

—

Observed

← altered in cohorts of

TP53

147 / 417 cases (35 %) · ssm · chol_icgc_2017 · largest of 17 cohorts

—

Observed

← altered in cohorts of

NBPF14

30 / 93 cases (32 %) · ssm · paad_iatlas_prince_2022

—

Observed

← altered in cohorts of

MUC17

21 / 93 cases (23 %) · ssm · paad_iatlas_prince_2022

—

Observed

Pancreatic Neuroendocrine Tumor

← altered in cohorts of

DAXX

22 / 98 cases (22 %) · ssm · panet_arcnet_2017 · largest of 2 cohorts

—

Observed

Pancreatic Neuroendocrine Tumor

← altered in cohorts of

ATRX

21 / 96 cases (22 %) · ssm · panet_msk_2018

—

Observed

Intrahepatic Cholangiocarcinoma

← altered in cohorts of

IDH1

85 / 412 cases (21 %) · ssm · ihch_msk_2021 · largest of 3 cohorts

—

Observed

← altered in cohorts of

ARID1A

80 / 417 cases (19 %) · ssm · chol_icgc_2017 · largest of 9 cohorts

—

Observed

← altered in cohorts of

ZNF814

20 / 109 cases (18 %) · ssm · paad_utsw_2015

—

Observed

Pancreaticobiliary Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 270show all (up to 200)
→ investigated in trials for	Gemcitabinesmall molecule 704 trials (141 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	704	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 256 trials (91 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	256	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 178 trials (47 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	178	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 159 trials (40 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	159	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 155 trials (29 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	155	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 134 trials (44 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	134	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 105 trials (37 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	105	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 101 trials (33 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	101	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 95 trials (38 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	95	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 71 trials (14 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	71	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 57 trials (29 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 57 trials (20 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 50 trials (15 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	50	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 42 trials (12 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 38 trials (11 active) · roll-up of the cancer and its descendants	—	—	Pancreaticobiliary Neoplasm	38	Observed	clinicaltrials	graph →

Pancreaticobiliary Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 270show all (up to 200)

→ investigated in trials for

Gemcitabinesmall molecule

704 trials (141 active) · roll-up of the cancer and its descendants

—

704

Observed

→ investigated in trials for

Nab-paclitaxel

256 trials (91 active) · roll-up of the cancer and its descendants

—

256

Observed

→ investigated in trials for

Fluorouracilsmall molecule

178 trials (47 active) · roll-up of the cancer and its descendants

—

178

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

159 trials (40 active) · roll-up of the cancer and its descendants

—

159

Observed

→ investigated in trials for

Capecitabinesmall molecule

155 trials (29 active) · roll-up of the cancer and its descendants

—

155

Observed

→ investigated in trials for

Cisplatinsmall molecule

134 trials (44 active) · roll-up of the cancer and its descendants

—

134

Observed

→ investigated in trials for

Irinotecansmall molecule

105 trials (37 active) · roll-up of the cancer and its descendants

—

105

Observed

→ investigated in trials for

Leucovorinsmall molecule

101 trials (33 active) · roll-up of the cancer and its descendants

—

101

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

95 trials (38 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

71 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

57 trials (29 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

57 trials (20 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

50 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

42 trials (12 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cetuximabmonoclonal antibody

38 trials (11 active) · roll-up of the cancer and its descendants

—

Observed

Pancreaticobiliary Neoplasm studied in …STUDIED_INderived10 of 5,004show all (up to 200)
→ studied in	NCT01824875Phase 2 · completed Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Glucagonoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 5,004 trials mapped (1,535 active)	—	—	Exocrine Pancreas Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02598349Phase 2 · recruiting Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas · condition mapped CURATED_EXACT · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04396821Phase 1/Phase 2 · active not recruiting A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors · condition mapped CURATED_EXACT · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04548752Phase 2 · active not recruiting Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04605913Phase 1/Phase 2 · active not recruiting Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped ALIAS · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05877599Phase 1 · recruiting A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 5,004 trials mapped (1,535 active)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05927142Phase 1/Phase 2 · active not recruiting Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06046794NA · recruiting Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · condition mapped ALIAS · 5,004 trials mapped (1,535 active)	—	—	Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →

Pancreaticobiliary Neoplasm studied in …STUDIED_INderived10 of 5,004show all (up to 200)

→ studied in

NCT01824875Phase 2 · completed

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors · condition mapped ALIAS · 5,004 trials mapped (1,535 active)

—

Pancreatic Glucagonoma

Observed

Exocrine Pancreas Carcinoma

→ studied in

NCT02465060Phase 2 · active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 5,004 trials mapped (1,535 active)

—

Observed

→ studied in

NCT02598349Phase 2 · recruiting

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas · condition mapped CURATED_EXACT · 5,004 trials mapped (1,535 active)

—

Observed

→ studied in

NCT04175912Phase 2 · active not recruiting

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)

—

Observed

→ studied in

NCT04396821Phase 1/Phase 2 · active not recruiting

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors · condition mapped CURATED_EXACT · 5,004 trials mapped (1,535 active)

—

Observed

→ studied in

NCT04548752Phase 2 · active not recruiting

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)

—

Observed

→ studied in

NCT04605913Phase 1/Phase 2 · active not recruiting

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC · condition mapped ALIAS · 5,004 trials mapped (1,535 active)

—

Pancreatic Carcinoma

Observed

→ studied in

NCT05877599Phase 1 · recruiting

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation · condition mapped ONTOLOGY_EXACT · 5,004 trials mapped (1,535 active)

—

Observed

→ studied in

NCT05927142Phase 1/Phase 2 · active not recruiting

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy · condition mapped CURATED_BROADER · 5,004 trials mapped (1,535 active)

—

Observed

→ studied in

NCT06046794NA · recruiting

Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · condition mapped ALIAS · 5,004 trials mapped (1,535 active)

—

Observed